-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 29, local time, after actively cooperating with the U.
Hemophilia B gene therapy Etranacogene dezaparvovec (AMT-061) is "highly unlikely" to cause liver cancer in patients
Hemophilia is a hereditary bleeding disorder caused by the lack or defect of coagulation factor IX.
AMT-061 is a gene therapy based on adeno-associated virus 5 (AAV-5) by uniQure following AMT-060.
In November last year, uniQure announced the results of a pivotal phase III clinical trial of AMT-061 called "HOPE-B".
One month later, uniQure announced the suspension of its phase III clinical trial for the treatment of hemophilia B.
On March 29, 2021, after nearly four months of investigation, uniQure announced that its AMT-061 gene therapy was "very unlikely" to cause lung cancer symptoms in patients with hemophilia B undergoing treatment.
In early February this year, Bluebird Bio also had such an oolong incident.
Currently, uniQure is preparing to negotiate with the FDA to resume its previously suspended clinical trials for hemophilia B.
Leave a message here
